drug_type
RELEVANT_DRUG
intervention_type
Drug (antibody-drug conjugate)
drug_description
An intravenous bispecific antibody-drug conjugate targeting EGFR and HER3. After binding and internalization, it releases the topoisomerase I inhibitor payload brengitecan, causing DNA damage and tumor cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific ADC that binds EGFR and HER3 on tumor cells, is internalized, and releases the topoisomerase I–inhibitor payload brengitecan, leading to DNA damage (via topo I inhibition) and tumor cell death, with potential bystander effect.
drug_name
BL-B01D1 (izalontamab brengitecan; BMS-986507)
nct_id_drug_ref
NCT05880706